The activation of the NLRP3 inflammasome has been associated with the pathogenesis of AD, therefore, targeting NLRP3 may help reduce neuroinflammation and slow down the progression of AD. Novel NLRP3 ...

(NASDAQ:VTYX), a biopharmaceutical company trading near its 52-week low of $1.67, has commenced Phase 2 trials for its NLRP3 inhibitor portfolio, targeting various inflammatory and ...

NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics, Inc., a leader in the developing class of selective NLRP3 inhibitors, today announced that long-time collaborator and advisor, Prof. Dr. Marc Donath ...